Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Radiopharmaceutical and antibody updates in neuroendocrine tumors at ESMO 2026

Francesca Spada, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses updates in neuroendocrine neoplasms at the European Society for Medical Oncology (ESMO) 2026 Congress, highlighting the evolution of nuclear medicine in well-differentiated tumors, the use of new antibodies in poorly differentiated neoplasms, and the growing importance of biomarkers. The congress featured promising results from a Phase I/IIa trial (NCT05636618) assessing [212Pb]VMT-a-NET and the use of new antibodies targeting PD-L1 and VEGF-A. This interview took place at the ESMO 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.